Perflutren Protein Type A Microspheres

Sharing is caring!

Perflutren Protein Type A Microspheres Brand Name– Optison

What is Perflutren Protein Type A Microspheres

Perflutren protein type A microspheres is an intravenous diagnostic agent used with ultrasonography to produce an echogenic contrast effect in the blood. Specifically, perflutren protein type A microspheres is indicated for administration to patients with suboptimal echocardiograms to enhance visualization of left ventricular endocardial borders.

Perflutren is an octafluoropropane, a fluorocarbon gas, that is encapsulated within an albumin shell to optimize the size of the gas bubble (2 to 4.5 micrometers) and improve stability.

During ultrasound examination, the gas-filled microspheres produce a lower impedence to the acoustic waves than does the surrounding blood, resulting in ultrasound waves that are scattered and reflected at the microsphere-blood interface. In addition, at frequency used during echocardiograms (2 to 5 MHz), the microspheres resonate which further increases the ultrasound scattering and reflecting.

The ultimate effect is enhanced visualization of the ultrasound image.

Prior to drug administration, ensure resuscitation equipment and trained personnel are readily available.

Perflutren protein type A microspheres is associated with serious cardiopulmonary adverse reactions.

Perflutren protein type A microspheres was FDA-approved in 1997


  • echocardiography
  • ultrasound imaging

For use during echocardiography to enhance ultrasound imaging by opacifying the left ventricle and improving the delineation of the left ventricular endocardial borders

NOTE: Diagnostic echocardiography procedures that involve the use of this product should be carried out under the direction of a licensed practitioner having a thorough knowledge of the procedure and the safe use of the product.

Side Effects

  1. anaphylactoid reactions
  2. angioedema
  3. arthralgia
  4. atrial fibrillation
  5. back pain
  6. blurred vision
  7. bradycardia
  8. bronchospasm
  9. cardiac arrest
  10. cardiopulmonary reaction
  11. chest pain (unspecified)
  12. chills
  13. coma
  14. cough
  15. dizziness
  16. dysgeusia
  17. dyspnea
  18. eosinophilia
  19. erythema
  20. fatigue
  21. fever
  22. flushing
  23. headache
  24. hypotension
  25. hypoxia
  26. injection site reaction
  27. irritability
  28. malaise
  29. myalgia
  30. nausea
  31. ocular irritation
  32. palpitations
  33. paresthesias
  34. photophobia
  35. pruritus
  36. rash
  37. respiratory arrest
  38. seizures
  39. sinus tachycardia
  40. syncope
  41. tinnitus
  42. tremor
  43. urticaria
  44. vomiting
  45. weakness
  46. wheezing
  47. xerostomia

Monitoring Parameters

  • laboratory monitoring not necessary


  • acute myocardial infarction
  • albumin hypersensitivity
  • arteriovenous shunt
  • breast-feeding
  • cardiopulmonary reaction
  • children
  • congenital heart disease
  • coronary artery disease
  • heart failure
  • infants
  • intraarterial administration
  • neonates
  • pregnancy
  • ventricular arrhythmias
  • viral infection


There are no drug interactions associated with Perflutren Protein Type A Microspheres products.

Sharing is caring!

What is recurrence

What is recurrence?  Recurrence refers to an initial reduction in...

You cannot copy content of this page


Sign up to receive the trending updates and tons of Health Tips

Join SeekhealthZ and never miss the latest health information

Scroll to Top